Blockade of CD11a by Efalizumab in Psoriasis Patients Induces a Unique State of T-Cell Hyporesponsiveness
- 1 May 2008
- journal article
- clinical trial
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 128 (5) , 1182-1191
- https://doi.org/10.1038/jid.2008.4
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- TISSUE DISTRIBUTION AND RECEPTOR-MEDIATED CLEARANCE OF ANTI-CD11A ANTIBODY IN MICEDrug Metabolism and Disposition, 2005
- T cell anergy and costimulationImmunological Reviews, 2003
- Increased CCR4 Expression in Cutaneous T Cell LymphomaJournal of Investigative Dermatology, 2002
- Psoriasis as a Model for T-Cell–Mediated DiseaseArchives of Dermatology, 2002
- Leukocyte adhesion deficiency syndromes: adhesion and tethering defects involving β 2 integrins and selectin ligandsCurrent Opinion in Hematology, 2002
- Genetic analysis of integrin function in man: LAD-1 and other syndromesMatrix Biology, 2000
- Bothanti-CD11a(LFA-l) and anti-CD11b (MAC-1) therapy delay the onset and diminish the severity of experimental autoimmune encephalomyelitisJournal of Neuroimmunology, 1995
- Leukocyte-endothelial adhesion moleculesBlood, 1994
- EVIDENCE THAT ANTI-ASIALO GM1 IN VIVO IMPROVES ENGRAFTMENT OF T CELL-DEPLETED BONE MARROW IN HYBRID RECIPIENTSTransplantation, 1990
- Mechanisms of monoclonal antibody‐facilitated tolerance induction: a possible role for the CD4 (L3T4) and CD11a (LFA‐1) molecules in self‐non‐self discriminationEuropean Journal of Immunology, 1988